Moreover, a more recent study by Louie et al. [20] demonstrated that GSTP1 is a driver of triple-negative breast cancer (TNBC) cell metabolism and pathogenicity and might be considered as a novel therapeutic target for this type of breast cancer. Here, GSTP1 is linked to triple-negative breast carcinoma.